BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21508296)

  • 21. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD).
    Petoumenos K; van Leuwen MT; Vajdic CM; Woolley I; Chuah J; Templeton DJ; Grulich AE; Law MG;
    HIV Med; 2013 Feb; 14(2):77-84. PubMed ID: 22934689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.
    Srasuebkul P; Lim PL; Lee MP; Kumarasamy N; Zhou J; Sirisanthana T; Li PC; Kamarulzaman A; Oka S; Phanuphak P; Vonthanak S; Merati TP; Chen YM; Sungkanuparph S; Tau G; Zhang F; Lee CK; Ditangco R; Pujari S; Choi JY; Smith J; Law MG
    Clin Infect Dis; 2009 Apr; 48(7):940-50. PubMed ID: 19226231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV.
    Ahn MY; Jiamsakul A; Khusuwan S; Khol V; Pham TT; Chaiwarith R; Avihingsanon A; Kumarasamy N; Wong WW; Kiertiburanakul S; Pujari S; Nguyen KV; Lee MP; Kamarulzaman A; Zhang F; Ditangco R; Merati TP; Yunihastuti E; Ng OT; Sim BLH; Tanuma J; Ratanasuwan W; Ross J; Choi JY;
    J Int AIDS Soc; 2019 Feb; 22(2):e25228. PubMed ID: 30803162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.
    Lincoln D; Petoumenos K; Dore GJ;
    HIV Med; 2003 Jul; 4(3):241-9. PubMed ID: 12859323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors and causes of death in the Australian HIV Observational Database.
    Petoumenos K; Law MG;
    Sex Health; 2006 May; 3(2):103-12. PubMed ID: 16800396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort.
    Tilley DM; Griggs E; Hoy J; Wright ST; Woolley I; Burke M; O'Connor CC;
    AIDS Care; 2015; 27(11):1410-7. PubMed ID: 26679270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
    Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
    PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database.
    Petoumenos K;
    J Clin Virol; 2003 Feb; 26(2):209-22. PubMed ID: 12600652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
    Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos AI; Katzenstein T; van Lunzen J; Antunes F; Phillips AN; Lundgren JD
    Ann Intern Med; 1999 Apr; 130(7):570-7. PubMed ID: 10189326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
    Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
    JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.
    Chen M; Wong WW; Law MG; Kiertiburanakul S; Yunihastuti E; Merati TP; Lim PL; Chaiwarith R; Phanuphak P; Lee MP; Kumarasamy N; Saphonn V; Ditangco R; Sim BL; Nguyen KV; Pujari S; Kamarulzaman A; Zhang F; Pham TT; Choi JY; Oka S; Kantipong P; Mustafa M; Ratanasuwan W; Durier N; Chen YM
    PLoS One; 2016; 11(3):e0150512. PubMed ID: 26933963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.
    Wright ST; Carr A; Woolley I; Giles M; Hoy J; Cooper DA; Law MG;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):72-9. PubMed ID: 21654498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term loss to follow-up in the TREAT Asia HIV Observational Database (TAHOD).
    Jiamsakul A; Kiertiburanakul S; Ng OT; Chaiwarith R; Wong W; Ditangco R; Nguyen KV; Avihingsanon A; Pujari S; Do CD; Lee MP; Ly PS; Yunihastuti E; Kumarasamy N; Kamarulzaman A; Tanuma J; Zhang F; Choi JY; Kantipong P; Sim B; Ross J; Law M; Merati TP;
    HIV Med; 2019 Aug; 20(7):439-449. PubMed ID: 30980495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
    Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
    Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
    Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
    JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.